Esperion to be Acquired by ARCHIMED
Esperion Therapeutics, Inc. • • business
Key Points:
- Esperion Therapeutics has agreed to be acquired by ARCHIMED in a transaction valued at up to approximately $1.1 billion, including contingent milestone payments tied to future sales performance.
- Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium over the April 30, 2026 closing price, plus rights to up to $100 million in aggregate contingent milestone payments.
- The milestone payments are based on future U.S. net sales of products containing bempedoic acid and bumetanide, with specific sales targets through 2030 triggering payments up to $100 million.
- The transaction, unanimously approved by Esperion’s Board, is expected to close in Q3 2026, after shareholder and regulatory approvals, after which Esperion will become a private company and delist from Nasdaq.
- Financing for the deal will be provided by Pharmakon Advisors, and both companies have engaged financial and legal advisors to support the transaction; Esperion will not hold its scheduled Q1 2026 earnings call due to the pending acquisition.
